Last reviewed · How we verify
NCT02982291
Focused Spinal Stenosis Rehabilitation Program for Lumbar Spinal Stenosis
NA trial testing Williams flexion protocol in Spinal Stenosis Lumbar. Withdrawn.
1 February 2018
Quick facts
| Lead sponsor | Hospital for Special Surgery, New York |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Start date | 1 May 2017 |
| Primary completion | 1 February 2018 |
| Estimated completion | 1 February 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Williams flexion protocol
- Focused spinal stenosis rehabilitation
Conditions studied
- Spinal Stenosis Lumbar — all drugs for Spinal Stenosis Lumbar →
Sponsor
Hospital for Special Surgery, New York
Who can join
40 and older, any sex, with Spinal Stenosis Lumbar. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lumbar spinal stenosis with neurogenic claudication is a common condition in the elderly population and is characterized by bilateral buttock, thigh, or calf discomfort and/or pain, as well as by weakness precipitated by walking and prolonged standing. Self-management options include physical therapy, which includes exercise as a core component for improving the flexibility and mobility of the spine and hips. A Williams flexion protocol has historically been used to treat low-back pain following degenerative changes to the posterior elements of the lumbar spine. However, few studies have been done to validate the efficacy of this protocol. A more focused treatment protocol may be more efficacious. Patients in this study will be randomized to receive either the generic physical therapy protocol (15 sessions) or the focused rehabilitation program (5 sessions). The sessions will take place over the course of 6 months. Outcomes will be assessed using validated questionnaires and physical function tests.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02982291
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spinal Stenosis Lumbar
Currently open trials in the same condition.
- NCT07348523 — Comparison of the Postoperative Analgesic Efficacy of Classical and Modified Erector Spinae Plane Blocks After Lumbar Sp · NA · recruiting
- NCT06367855 — Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF · Phase 4 · recruiting
- NCT06393959 — Relief of Lumbar Spinal Stenosis Symptoms · NA · recruiting
- NCT05253326 — The Effect of Progressive Muscle Relaxation Exercises on Pain and Disability After Spinal Surgery · NA · recruiting
Other Hospital for Special Surgery, New York trials
Trials by the same sponsor.
- NCT07226700 — Suzetrigine in Total Hip Arthroplasty · Phase 3 · recruiting
- NCT06567873 — Gastric Ultrasound Assessment for Patients Taking Cannabis · completed
- NCT07217964 — Natural Matrix Protein · enrolling by invitation
- NCT06798493 — CSS-SR Validation Study · enrolling by invitation
- NCT06180486 — Mindfulness Meditation Intervention Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02982291 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital for Special Surgery, New York
- Last refreshed: 5 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02982291.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing